Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2019 / N 3

Новые оральные антикоагулянты – окончательное решение проблемы профилактики инсульта при фибрилляции предсердий?
А.В. Мелехов, Г.Е. Гендлин, Э.Ф. Дадашова, И.И. Захарова, С.И. Варенцов

References

1. Shah A, Shewale A, Hayes CJ, Martin BC. Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke 2016 Jun;47(6):1555-61.
2. Salcedo J, Hay JW, Lam J. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. International Journal of Cardiology 2019 May;282:53-8.
3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016 Oct;37(38):2893-962.
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. The Lancet 2014 Mar;383(9921):955-62.
5. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. The Lancet 2010 Sep;376(9745):975-83.
6. Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Investigators. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. Journal of the American Heart Association 2014 Apr;3(2):e000521.
7. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, Carrier M, Coyle K, Bai A, Moulton K, Clifford T, Wells G. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014 Jun;4(6):e004301.
8. Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clinical Pharmacology 2016 Aug;8:93-107.
9. Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart 2016 Jan;3(1):e000279.
10. He Q, Sze CY, Shum TY, Hao G, Wong NB, Sin TH, Wei W, Xia S. Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with valvular heart diseases: a meta-analysis. BMC Cardiovascular Disorders 2019 May;19(1):113.
11. Oktay E. Will NOACs become the new standard of care in anticoagulant therapy? International Journal of the Cardiovascular Academy 2015;1:1-4.
12. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016 Jun;353:i3189.
13. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion 2017 Sep;33(9):1595-604.
14. Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of Defense population. Journal of Managed Care & Specialty Pharmacy 2018 Nov;24(11):1116-27.
15. Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. The American Journal of Medicine 2019 May;132(5):596-604.e11.
16. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thrombosis and Haemostasis 2015 Nov;114(6):1277-89.
17. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thrombosis and Haemostasis 2017 Jun;117(6):1072-82.
18. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. The American Journal of Cardiology 2017 Nov;120(10):1813-9.
19. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace 2018 Mar;20(3):420-8.
20. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. The American Journal of Medicine 2018 Sep;131(9):1075-85.e4.
21. Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. Journal of Clinical Medicine 2019 Apr;8(4). pii: E554. doi: 10.3390/jcm8040554.
22. Robson J, Mathur R, Priebe M, Ahmed Z, Ayerbe L. Thromboembolic and haemorrhagic events in patients with atrial fibrillation: a prospective cohort study in UK primary and secondary care. The British Journal of General Practice 2019 Jun;69(683):e407-12.
23. Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E. Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: a nationwide pharmacoepidemiological study. PLoS One 2019 Aug;14(8):e0221500.
24. Lee SR, Choi EK, Kwon S, Han KD, Jung JH, Cha MJ, Oh S, Lip GYH. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. Stroke 2019 Aug;50(8):2245-9.
25. Shpak M, Ramakrishnan A, Nadasdy Z, Cowperthwaite M, Fanale C. Higher incidence of ischemic stroke in patients taking novel oral anticoagulants. Stroke 2018 Dec;49(12):2851-6.
26. How CH. Novel oral anticoagulants for atrial fibrillation. Singapore Medical Journal 2015 Dec;56(12):657-8; quiz 659.
27. Jayaraman DK, Alcusky M, Moonis M. Letter by Jayaraman et al regarding articles, "Higher incidence of ischemic stroke in patients taking novel oral anticoagulants" and "Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study". Stroke 2019 Jun;50(6):e154-5.
28. Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U. Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmatic and Observational Research 2018 May;9:1-10.
29. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015 Jan;131(2):157-64.
30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2009 Sep;361(12):1139-51.
31. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(10):883-91.
32. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine 2011 Sep;365(11):981-92.
33. Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current Medical Research and Opinion 2014 Jul;30(7):1317-25.
34. Bancroft T, Lim J, Wang C, Sander SD, Swindle JP. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clinical Therapeutics 2016 Mar;38(3):545-56.e1-6.
35. Al-Khalili F, Lindström C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Current Medical Research and Opinion 2016;32(4):779-85.
36. Maura G, Blotière P-O, Bouillon K, Ricordeau P, Alla F, Zureik M. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015 Sep;132(13):1252-60.
37. Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thrombosis and Haemostasis 2008 Dec;100(6):1052-7.
38. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008 Nov;118(20):2029-37.
39. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013 Jun;127(22):2166-76.
40. Mueller S, Pfannkuche M, Breithardt G, Bauersachs R, Maywald U, Kohlmann T, Wilke T. The quality of oral anti-coagulation in general practice in patients with atrial fibrillation. European Journal of Internal Medicine 2014 Mar;25(3):247-54.
41. Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation (DARING-AF). ClinicalTrials.gov Identifier: NCT02666157. NIH, U.S. National Library of Medicine, ClinicalTrials.com. Available from: https://clinicaltrials.gov/ct2/show/NCT02666157 Accessed 2019 Nov 13.
42. The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation (DANNOAC-AF). ClinicalTrials.gov Identifier: NCT03129490. NIH, U.S. National Library of Medicine, ClinicalTrials.com. Available from: https://clinicaltrials.gov/ct2/show/NCT03129490 Accessed 2019 Nov 13.
43. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thrombosis and Haemostasis 2016 Sep;116(4):754-63.
44. Bai Y, Shi XB, Ma CS, Lip GYH. Meta-analysis of effectiveness and safety of oral anticoagulants in atrial fibrillation with focus on apixaban. The American Journal of Cardiology 2017 Nov;120(9):1689-5.
45. Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis. Stroke 2017 Apr;48(4):970-6.
46. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 2017 Sep;48(9):2494-503.
47. Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M, Horblyuk R, Ashaye A. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Current Medical Research and Opinion 2017 Sep;33(9):1583-94.
48. Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis. Journal of the American Heart Association 2019 Jul;8(14):e012540.
49. Xue Z, Zhang H. Non-vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies. Stroke 2019 Oct;50(10):2819-28.
50. Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA. Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation. Pharmacotherapy 2017 Oct;37(10):1221-30.
51. Rodriguez-Bernal CL, Peiró S, Hurtado I, García-Sempere A, Sanfélix-Gimeno G. Primary nonadherence to oral anticoagulants in patients with atrial fibrillation: real-world data from a population-based cohort. Journal of Managed Care & Specialty Pharmacy 2018 May;24(5):440-8.
52. Ruigómez A, Vora P, Balabanova Y, Brobert G, Roberts L, Fatoba S, Fernandez O, García Rodríguez LA. Discontinuation of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from the Health Improvement Network in the UK. BMJ Open 2019 Oct;9(10):e031342.
53. Cataldo N, Pegoraro V, Ripellino C, Bertasi V, Di Turi R, Pastorello M, Gambera M. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Recenti Progressi in Medicina 2018 Feb;109(2):113-21.
54. Sørensen R, Jamie Nielsen B, Langtved Pallisgaard J, Ji-Young Lee C, Torp-Pedersen C. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. European Heart Journal Cardiovascular Pharmacotherapy 2017 Jul;3(3):151-6.
55. Kim H, Lee YS, Kim TH, Cha MJ, Lee JM, Park J, Park JK, Kang KW, Shim J, Uhm JS, Park HW, Choi EK, Kim JB, Kim C, Kim J, Joung B. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF). Korean Journal of Internal Medicine 2019 Apr 25. doi: 10.3904/kjim.2017.415. [Epub ahead of print].
56. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thrombosis and Haemostasis 2016 Jan;115(1):31-9.
57. Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A. Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French National Health Care Databases. Pharmacotherapy 2018 Jan;38(1):6-18.
58. Wu S, Xie S, Xu Y, Que D, Yau TO, Wang L, Huang Y. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation. Journal of Clinical Nursing 2019 May;28(9-10):1839-46.
59. Liu C, Du X, Jiang C, He L, Chang SS, Guo XY, Yu RH, Long DY, Bai R, Liu N, Sang CH, Jiang CX, Dong JZ, Lip GYH, Ma CS. Long-term persistence with newly-initiated warfarin or Non-VKA Oral Anticoagulant (NOAC) in patients with non-valvular atrial fibrillation: insights from the prospective China-AF registry. Medical Science Monitor 2019 Apr;25:2649-57.
60. Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G, Maguire A. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: a cohort study using primary care data in Germany. PLoS One 2017 Oct;12(10):e0185642.
61. Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European Heart Journal 2019 May;40(19):1492-500.
62. Sørensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbøl EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Køber L, Weeke P, Lip GY, Hansen ML. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013 May;3(5). pii: e002758.
63. Carley B, Griesbach S, Larson T, Krueger K. Assessment of dabigatran utilization and prescribing patterns for atrial fibrillation in a physician group practice setting. The American Journal of Cardiology 2014 Feb;113(4):650-4.
64. Howard M, Lipshutz A, Roess B, Hawes E, Deyo Z, Burkhart JI, Moll S, Shilliday BB. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. Journal of Thrombosis and Thrombolysis 2017 Feb;43(2):149-56.
65. Viprey M, Jeannin R, Piriou V, Chevalier P, Michel C, Aulagner G, Berthiller J, Armoiry X. Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study. Journal of Clinical Pharmacy and Therapeutics 2017 Feb;42(1):58-63.
66. Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. Journal of the American Heart Association 2013 Nov;2(6):e000535.
67. Ruiz Ortiz M, Muñiz J, Raña Míguez P, Roldán I, Marín F, Asunción Esteve-Pastor M, Cequier A, Martínez-Sellés M, Bertomeu V, Anguita M; FANTASIIA study investigators. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace 2018 Oct;20(10):1577-83.
68. Melekhov AV. Management of patients with cardiovascular diseases that increase the risk of stroke [Dissertation for Degree of the Doctor of Medical Sciences]. Moscow, 2019. 281 p. (In Russian).
69. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal 2018 Apr;39(16):1330-93.
70. Yakusheva EN, Shchulkin AV, Popova NM, Chernykh IV, Titov DS. Structure and functions of glycoprotein-P, and its role in rational pharmacotherapy. Reviews on Clinical Pharmacology and Drug Therapy 2014;12(2):3-11 (In Russian).
71. Chowdhury R, Franchino-Elder J, Wang L, Yuce H, Wang C, Hartaigh BO. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. Journal of Medical Economics 2019 Dec;22(12):1338-50.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]